Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To investigate the differences in peripheral blood levels of interleukin-1β (IL-1β), IL-6, IL-17, and IL-33 between patients with chronic obstructive pulmonary disease (COPD) and lung cancer (Comorbidity Group) and those with COPD alone (COPD Group), as well as to explore their clinical significance.
Methods: Samples were collected from 133 patients with both COPD and lung cancer (Comorbidity Group) and 91 patients with COPD alone (COPD Group), diagnosed at Affiliated Hospital of Inner Mongolia Medical University between January 2022 and January 2024. Baseline data from both groups were analyzed, and peripheral blood levels of IL-1β, IL-6, IL-17, and IL-33 were measured using enzyme-linked immunosorbent assay (ELISA). The levels of these inflammatory cytokines were compared between the two groups to assess their correlation with disease severity.
Results: Significant differences were observed between the Comorbidity Group and the COPD Group in terms of age (P<0.001), sex (P=0.012), duration of COPD (P=0.001), smoking history (P=0.006), glucocorticoid treatment (P=0.014), and GOLD Staging (P<0.001). IL-1β was positively correlated with RV/TLC (P=0.036), and IL-17 with FEV1 (P=0.027) in both groups. IL-6 was positively correlated with TLC in the Comorbidity Group (P=0.021). In the COPD Group, IL-33 was negatively correlated with FEV1 (P<0.001), FVC (P=0.001), FEV1/FVC (P<0.001), RV (P<0.001), and RV/TLC (P<0.001), and positively correlated with GOLD Staging (P=0.046). Multivariate logistic regression identified smoking history (P=0.045, OR=2.891), GOLD staging (P=0.028, OR=0.363), IL-33 (P=0.001, OR=27.369), FEV1/FVC (P=0.012, OR=4.291), RV (P=0.002, OR=5.429), and RV/TLC (P=0.002, OR=6.113) as independent factors distinguishing patients with comorbid COPD and lung cancer from those with COPD alone. Interaction analysis revealed no significant interaction between IL-33 and other risk factors.
Conclusion: IL-33 levels were significantly higher in patients with comorbid COPD and lung cancer than in those with COPD alone. IL-33 was negatively correlated with lung function and positively correlated with GOLD Staging, suggesting its potential as a biomarker for disease severity.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256424 | PMC |
| http://dx.doi.org/10.62347/QCSN6467 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of dupilumab and mepolizumab in eosinophilic COPD: insights from phase 3 trials.
Respir Med
September 2025
Scottish Centre for Respiratory Research, School of Medicine, University of Dundee, Dundee, United Kingdom. Electronic address:
Background: Eosinophilic chronic obstructive pulmonary disease (eCOPD), characterized by type 2 inflammation, is an emerging target for biologic therapies.
Objective: To indirectly compare the efficacy of dupilumab and mepolizumab in eCOPD, defined as blood eosinophil counts ≥300 cells/μL, by synthesizing data from phase 3 randomized controlled trials: BOREAS and NOTUS for dupilumab, MATINEE for mepolizumab.
Methods: We performed an indirect comparison of trial primary and secondary outcomes including annual exacerbation rates (AER), quality of life (St.
Quantitative correlation between small airway morphology with respiratory function during disease progression in COPD: CFD analysis of human airways based on CT and OCT imaging.
Comput Methods Programs Biomed
September 2025
School of Biological Sciences and Medical Engineering, Southeast University, Nanjing, Jiangsu, China. Electronic address:
Background And Objective: The quantitative knowledge of the influence of the small airway disease on the functional changes in chronic obstructive pulmonary disease (COPD) patients has been severely limited.
Methods: This study presents an innovative patient-specific computational framework that integrates CT and OCT imaging data with multiscale computational fluid dynamics (CFD) analysis. A three-dimensional tracheobronchial tree is reconstructed from CT scans of a mild COPD patient, spanning from the central airway to the 4th generation bronchial bifurcations.
Air pollution and diseases: signaling, G protein-coupled and Toll like receptors.
Pharmacol Ther
September 2025
Department of Molecular Pharmacology, University of Groningen, Groningen, the Netherlands; Groningen Research Institute for Asthma and COPD, GRIAC, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. Electronic address:
Air pollution is a significant public health issue that impacts lung health, particularly in vulnerable populations such as children, the elderly, and individuals with pre-existing respiratory conditions. Both natural and anthropogenic sources of air pollution give rise to a variety of toxic compounds, including particulate matter (PM), ozone (O₃), sulfur dioxide (SO₂), nitrogen dioxide (NO₂), carbon monoxide (CO), and polycyclic aromatic hydrocarbons (PAHs). Exposure to these pollutants is strongly associated with the development and exacerbation of respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), lung cancer, and idiopathic pulmonary fibrosis (IPF).
View Article and Find Full Text PDFAssessing inpatient formulary-driven inhaler use in presumed Group B chronic obstructive pulmonary disease.
J Am Pharm Assoc (2003)
September 2025
WVU Medicine - WVU Hospitals; Morgantown, WV; West Virginia University School of Pharmacy; Morgantown, WV.
Background: Long-acting muscarinic antagonist (LAMA) and long-acting beta agonist (LABA) combination maintenance therapy is recommended for patients with Group B chronic obstructive pulmonary disease (COPD) in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. Exposure to inhaled corticosteroids (ICS) in these patients may increase adverse effects without adding clinical benefit. Inpatient formulary limitations may facilitate unnecessary exposure to ICS and ICS-associated adverse events while hindering the use of optimal LAMA/LABA inhaler therapy in Group B COPD patients.
View Article and Find Full Text PDFComparison of Underlying Risk of Developing and Dying from Lung Cancer in Screened Populations.
Chest
September 2025
Department of Radiology, The University of North Carolina, Chapel Hill, NC; Lineberger Comprehensive Cancer Center, The University of North Carolina, Chapel Hill, NC.
Background: Trial participants are typically healthier than the general population. Differences in underlying characteristics between the population undergoing lung cancer screening (LCS) and LCS trial participants may alter the benefits of LCS.
Research Question: Does the risk of developing and dying from lung cancer differ between trial participants and the general population?
Study Design And Methods: Using data from the i) North Carolina Lung Screening Registry (NCLSR), ii) 2022 Center for Disease Control and Prevention's Behavioral Risk Factor Surveillance System (BRFSS) Lung Cancer Screening Module, and iii) National Lung Screening Trial (NLST), we estimated the 5-year probability of developing and dying from lung cancer if not screened using publicly available macros.